Press Release (U.S.A. version) – Outside U. S. A. version follows after U. S. A. version
Montvale, NJ – January 9, 2017 – PENTAX Medical, a division of the HOYA Group, Tokyo, Japan announced today that they have acquired C2 Therapeutics, Redwood City, CA for an undisclosed amount. C2 Therapeutics develops the C2 CryoBalloon™ Ablation System for the endoscopic ablation of unwanted tissue such as Barrett’s esophagus1. This acquisition will help strengthen the company’s therapeutic endoscopy portfolio.
C2 Therapeutics Announces Initiation of Coldplay III Trial Validating The C2 CryoBalloon™ Focal Ablation System for Primary Treatment of Barrett’s Esophagus
REDWOOD CITY, Calif. – June 7, 2016 – C2 Therapeutics today announced the initiation of its Coldplay III trial with treatment of the first patient at University Hospitals in northeast Ohio. The patient was treated with the C2 CryoBalloon™ Focal Ablation System by John Dumot, D.O., Director, Digestive Health Institute, University Hospitals, commencing the clinical trial to validate the efficacy and safety of the system in patients with Barrett’s esophagus.
C2 Therapeutics Announces Data from Four Studies Reinforcing the Safety and Efficacy of its C2 CryoBalloon™ Focal Ablation System
REDWOOD CITY, Calif. – May 24, 2016 – C2 Therapeutics, a privately-held medical device company founded to improve methods of eradicating unwanted tissue in endoscopic applications, today announced new data from four separate clinical studies designed to assess the safety and efficacy of its C2 CryoBalloon™ Focal Ablation System (CbFAS). The data, which support the safety and efficacy of the company’s CbFAS, were presented at Digestive Disease Week (DDW) 2016, which is taking place May 21 – 24 in San Diego.
Redwood City, Calif. – October 22, 2015 – C2 Therapeutics, a privately-held company founded to improve treatment of precursors to esophageal cancer (Barrett’s Esophagus or BE), today announced that it received the CE (Conformité Européenne) mark for its Coldplay CryoBalloon® Focal Ablation System. The product is now available for commercial use initially in parts of Western Europe. Cryoablation is a process that uses extreme cold to precisely destroy or damage diseased tissue while minimizing damage to surrounding healthy tissue.
Redwood City, Calif. – July 29, 2015 – C2 Therapeutics, a privately held company founded to improve treatment of precursors to esophageal cancer (Barrett’s Esophagus or BE), today announced US Food and Drug Administration (FDA) 510(k) clearance for the Coldplay Cryoballoon™ Full Ablation System and the Coldplay Cryoballoon™ Swipe Ablation System.
“The clearance of Coldplay Cryoballoon Full and Swipe Systems is an important milestone in broadening the company’s portfolio,” said Peter Garcia-Meza, President and CEO of C2 Therapeutics. “The Full and Swipe Ablation Systems will be critical in allowing physicians to ablate larger areas of tissue in endoscopic applications.”
Redwood City, Calif. – July 20, 2015 – C2 Therapeutics, a privately held company founded to improve treatment of precursors to esophageal cancer (Barrett’s Esophagus or BE), today announced the publication of excellent safety and dosing data related to the company’s Coldplay Cryoballoon™ Focal Ablation System. Results from the prospective, non-randomized study titled, “Treatment of Barrett’s Esophagus with a novel focal cryoablation device: a safety and feasibility study” were published in the latest edition of the scientific journal Endoscopy.